TABLE 1.
Ribavirin treatment characteristics and outcome in chronic hepatitis E patients
| Author (year) | n | Ribavirin dose, range | Duration of therapy, median (range) in months | RVR, n (%) | SVR, n (%) | Relapses, n (%) | Non‐responder, n (%) |
|---|---|---|---|---|---|---|---|
| Choi (2018) | 16 | 85.7–1000 mg/day | 3.8 (2.9) a | NR | 11 (69) | 5 (31) | |
| Cordts (2018) | 4 | 3.6–15.4 mg/kg/day | 3 (2–3) | 4 (100) | 3 (75) | 1 (25) | |
| Darstein (2018) | 4 | 400–1000 mg/day | 4 (1‐6) | 2 (50) | 4 (100) | ||
| Debing (2014) | 14 | 600–1000 mg/day | NR | NR | 13 (93) | 1 (7) | |
| Galante (2015) | 4 | 400–800 mg/day | 3 (3–6) | 1 (25) | 3 (75) | 1 (25) | |
| Gallian (2019) | 10 | NR | 5.5 (1.5–5) | NR | 8 (80) | 2 (20) | |
| Hewitt (2014) | 1 | NR | 3 | 1 (100) | |||
| Junge (2013) | 1 | 400 mg/day | 6 | 1 (100) | |||
| Kamar (2010a) | 6 | 400–800 mg/day | 3 | 5 (83) | 4 (67) | 2 (33) | |
| Kamar (2012a) | 9 | NR | 3 | 5 (42)* | 9 (100) | ||
| Kamar (2014) | 59 | 29–1200 mg/day | 3 (1–18) | 32 (54) | 46 (78) | 10 (17) | 3 (5) |
| Koning (2013) | 4 | 200–600 mg/day | 6 (3–9) | 2 (50) | 1 (25) | 1 (25) | |
| Lens (2015) | 4 | 600–800 mg/day | 3 | 3 (75) | 3 (75) | 1 (25) | |
| Lhomme (2016) | 23 | 600–800 mg/day | 3 (3–18) | NR | 10 (43) | 11 (48) | 2 (9) |
| Lhomme (2019) | 41 | 200–1200 mg/day | 3 | NR | 25 (61) | 13 (32) | 3 (7) |
| Low (2019) | 9 | 400–800 mg/day | 3 | 3 (33) | 4 (44) | 2 (22) | |
| Mallet (2018) | 3 | 10 mg/kg/day | 3 | NR | 3 (100) | ||
| Marion (2018) | 43 | 9.4 (0.5) mg/kg/day a | 3 | 19 (44) | 35 (81) | 8 (19) | |
| Marion (2019) | 48 | 9.7 (3.1) mg/kg/day a | 3 (3–15) | 17 (35) | 39 (81) | 9 (19) | |
| Nijskens (2016) | 26 | 800 mg/day | 3 (0.3–18) | 7 (27) | 25 (96) | 1 (4) | |
| Owada (2020) | 3 | NR | 3 | 3 (100) | |||
| Pischke (2012) | 4 | 200‐800 mg/day | 5 | 2 (50) | 3 (75) | 1 (25) | |
| Pischke (2013) | 7 | 600–1000 mg/day | 5 | 2 (29) | 6 (86) | 1 (14) | |
| Pischke (2014) | 1 | 200–600 mg/day | 5 | 1 (100) | |||
| Pischke (2019) | 5 | 600 mg/day | 5 (3–6) | 4 (80) | 1 (20) | ||
| Reekie (2018) | 1 | NR | NR | 1 (100) | |||
| Riezebos‐Brilman (2013a) | 5 | 800 mg/day | 4 (0.5–4) | 5(100) | |||
| Riezebos‐Brilman (2013b) | 2 | 800 mg/day | 4 | 2 (100) | |||
| Sridhar (2018a) | 3 | NR | 8 (3–22) | 2 (66) | 1 (33) | ||
| Sridhar (2018b) | 1 | 800 mg/day | 8 | 1 (100) | |||
| Sridhar (2019) | 4 | 200–400 mg/day | NR | 3 (75) | 1 (25) | ||
| Todt (2016) | 9 | 600‐1000 mg/day | 5 (4–10) | 5 (56) | 4 (44) | ||
| von Felden (2019) | 19 | 5.0–22.0 mg/kg/day | 3 (1–32) | NR | 16 (84) | 3 (16) | |
| Xhaard (2019) | 2 | NR | 4.5 (3–6) | 2 (100) | |||
| Total | 395 |
29–1200 mg/day 3.6–22.0 mg/kg/day |
3 (0.3–32) | 99/395 (25) | 301/395 (76) | 72/395 (18) | 22/395 (6) |
Abbreviations: NR, not reported; RVR, rapid virological response; SVR, sustained virological response.
a
Mean (SD).